Joe Biden’s global corporation tax deal: A prediction on what’s next
Why have the nations of the world agreed to a new minimum corporation tax rate? And what happens to so-called…
By
Business & Regulation
Latest in
Business & Regulation
Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination
Sanofi’s pemphigus asset, Artios solid tumor trial among recent events reviewed by GlobalData’s Investigative News team.
By
Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
By
Multiple myeloma: first bispecific mAb to secure r/r approval will have biggest market bite
Market latecomers will likely struggle to demonstrate value-added edge so early strategic decisions are critical.
By
Regulatory roundup: Akeso’s bispecific antibody moves closer to approval in China
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
By
Novavax Covid-19 vaccine booster: safety and manufacturing questions remain
Novavax’s Covid-19 vaccine could find its niche as a booster shot, but questions linger around its safety and production.
By
Regulatory roundup: Alexion ALS drug sees approval prospects plummet
GlobalData’s Investigative News team reviews recent events that impacted a drug’s path to regulatory approval.
By
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said.
By